Current perspectives on tertiary lymphoid structures and PD-1/PD-L1 signaling pathway in the immunotherapy of hepatocellular carcinoma
In the entire world, hepatocellular carcinoma (HCC) is one of the most prevalent cancers. The discovery that HCC is intimately linked to programmed cell death-1 and its ligand (PD-1/PD-L1) in recent years has opened up new possibilities for immunotherapy. However, there are no reliable biomarkers fo...
Saved in:
Main Authors: | Hao-Dong QIAO, Yi-Fan LIU, Ze LIANG, Huai-Bin GUO |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of New Medicine
2023-10-01
|
Series: | Yixue xinzhi zazhi |
Subjects: | |
Online Access: | https://yxxz.whuznhmedj.com/futureApi/storage/attach/2310/ObvDqjvIUH3aNnde6f2OXTYE9hQVp1koUOzbPg9z.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment
by: Xu Liu, et al.
Published: (2024-12-01) -
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
by: Annapaola Montagner, et al.
Published: (2024-12-01) -
From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment
by: Fang-Ju Huang, et al.
Published: (2025-12-01) -
The potential role of HPV oncoproteins in the PD-L1/PD-1 pathway in cervical cancer: new perspectives on cervical cancer immunotherapy
by: Jin Li, et al.
Published: (2024-12-01) -
Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma
by: JIANG Jiayun, et al.
Published: (2024-11-01)